

UNITED STATES PATENT APPLICATION

**CARDIAC RHYTHM MANAGEMENT SYSTEM SYNCHRONIZING  
ATRIAL SHOCK TO VENTRICULAR DEPOLARIZATION BASED  
ON LENGTH OF SENSING REFRACTORY**

**INVENTOR**

Gary T. Seim  
of Minneapolis, Minnesota, U.S.A.

**Attorney: Suneel Arora**

Reg. No. 42,267

Schwegman, Lundberg, Woessner, & Kluth, P.A.

1600 TCF Tower

121 South Eighth Street

Minneapolis, Minnesota 55402

ATTORNEY DOCKET NO. 00279.363US1

# **CARDIAC RHYTHM MANAGEMENT SYSTEM SYNCHRONIZING ATRIAL SHOCK TO VENTRICULAR DEPOLARIZATION BASED ON SENSING REFRACTORY**

## **Cross Reference To Related Applications**

5           This application is related to the following co-pending, commonly assigned U.S. patent applications: "Cardiac Rhythm Management System With Atrial Shock Timing Optimization," serial number 09/316,741 and "Method for Delivering Atrial Defibrillation Therapy," serial number 09/661,875. The disclosure of each of these patent applications is herein incorporated by reference in its entirety.

10

## **Technical Field**

          The present system relates generally to cardiac rhythm management systems and particularly, but not by way of limitation, to such a system that synchronizes delivery of an atrial shock to a ventricular depolarization based at least in part on the  
15   nature of a refractory period following a ventricular depolarization.

## **Background**

          When functioning properly, the human heart maintains its own intrinsic rhythm, and is capable of pumping adequate blood throughout the body's circulatory  
20   system. However, some people have irregular cardiac rhythms, referred to as cardiac arrhythmias. Such arrhythmias result in diminished blood circulation. One mode of treating cardiac arrhythmias uses drug therapy. Drugs are often effective at restoring normal heart rhythms. However, drug therapy is not always effective for treating arrhythmias of certain patients. For such patients, an alternative mode of  
25   treatment is needed. One such alternative mode of treatment includes the use of a cardiac rhythm management system. Such systems are often implanted in the patient and deliver therapy to the heart.

          Cardiac rhythm management systems include, among other things, pacemakers, also referred to as pacers. Pacers deliver timed sequences of low  
30   energy electrical stimuli, called pace pulses, to the heart, such as via an intravascular

leadwire or catheter (referred to as a “lead”) having one or more electrodes disposed in or about the heart. Heart contractions are initiated in response to such pace pulses (this is referred to as “capturing” the heart). By properly timing the delivery of pace pulses, the heart can be induced to contract in proper rhythm, greatly improving its efficiency as a pump. Pacers are often used to treat patients with bradyarrhythmias, that is, hearts that beat too slowly, or irregularly. Such pacers coordinate atrial and ventricular contractions to improve pumping efficiency. Cardiac rhythm management systems also include coordination devices for coordinating the contractions of both the right and left sides of the heart for improved pumping efficiency.

- 10 Cardiac rhythm management systems also include defibrillators that are capable of delivering higher energy electrical stimuli to the heart. Such defibrillators also include cardioverters, which synchronize the delivery of such stimuli to portions of sensed intrinsic heart activity signals. Defibrillators are often used to treat patients with tachyarrhythmias, that is, hearts that beat too quickly.
- 15 Such too-fast heart rhythms also cause diminished blood circulation because the heart isn’t allowed sufficient time to fill with blood before contracting to expel the blood. Such pumping by the heart is inefficient. A defibrillator is capable of delivering a high energy electrical stimulus that is sometimes referred to as a defibrillation countershock, also referred to simply as a “shock.” The countershock
- 20 interrupts the tachyarrhythmia, allowing the heart to reestablish a normal rhythm for the efficient pumping of blood. In addition to pacers, cardiac rhythm management systems also include, among other things, pacer/defibrillators that combine the functions of pacers and defibrillators, drug delivery devices, and any other implantable or external systems or devices for diagnosing or treating cardiac
- 25 arrhythmias.

One problem faced by cardiac rhythm management systems is the detection and treatment of atrial tachyarrhythmias, such as atrial fibrillation, in which one or both of the atrial heart chambers incoherently depolarizes in a rapid and chaotic fashion. Atrial fibrillation is a common cardiac arrhythmia that reduces the

pumping efficiency of the heart, though not to as great a degree as ventricular fibrillation. However, this reduced atrial pumping efficiency forces the corresponding ventricle to work harder, which is particularly undesirable in sick patients that cannot tolerate additional stresses. Atrial fibrillation also causes variability in the ventricular heart rate, which is noticeable and uncomfortable for the patient. As a result of atrial fibrillation, patients must typically limit their activity and exercise.

Although atrial fibrillation, by itself, is usually not life-threatening, prolonged atrial fibrillation may be associated with strokes, which are thought to be caused by blood clots forming in areas of stagnant blood flow. Treating such blood clots may require the use of anticoagulants. Atrial fibrillation may also cause pain, tiredness, dizziness, and other irritation to the patient.

An even more serious problem, however, is the risk that atrial fibrillation may induce irregular ventricular heart rhythms by processes that are yet to be fully understood. Moreover, treatment of atrial fibrillation may also induce irregular ventricular heart rhythms. Such induced ventricular arrhythmias compromise pumping efficiency even more drastically than atrial arrhythmias and, in some instances, may be life-threatening. For these and other reasons, there is a need for safe and more effective treatment of atrial fibrillation that avoids inducing ventricular arrhythmias.

### **Summary of the Invention**

This document describes a cardiac rhythm management system that, among other things, synchronizes the delivery of an atrial defibrillation shock to a ventricular depolarization concluding a present RR interval since the occurrence of the last ventricular depolarization. The present RR interval is deemed “shockable” if, among other things, its ventricular refractory period (VRP), which may be extended by ventricular “noise” occurring during the VRP, is less than a predetermined value or, alternatively, if a post-VRP time period before the ventricular depolarization concluding the present RR interval exceeds a

predetermined value. In conjunction with one or both of these conditions, other requirements for deeming a present RR interval shockable include comparing the present RR interval duration to a predetermined value, or to a preceding RR or QT interval. Also in conjunction with one or both of these conditions, is excluding from being shockable a present RR interval that is initiated by a paced ventricular depolarization and concluded by a sensed ventricular depolarization.

In one embodiment, the system includes a method in which an episode of atrial fibrillation is detected in an atrium. The system senses ventricular depolarizations, and measures a duration of a present RR interval since a most recent ventricular depolarization. The system delivers an atrial defibrillation shock synchronized to (albeit permissibly delayed a bit from) a ventricular depolarization, which concludes a present RR interval, if the present RR interval is shockable. A shockable present RR interval requires, among other things, that a ventricular sensing refractory period of the present RR interval is less than or equal to a first predetermined value or that a minimum sensing time period exists between the expiration of a ventricular refractory period (VRP) and a subsequent ventricular depolarization. The system also includes structures for performing this and other methods, as discussed below.

### **Brief Description of the Drawings**

In the drawings, which are not necessarily drawn to scale, like numerals describe substantially similar components throughout the several views. Like numerals having different letter suffixes represent different instances of substantially similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.

Figure 1 is a schematic/block diagram illustrating generally, among other things, one embodiment of portions of a cardiac rhythm management system and an environment in which it is used.

Figure 2 is a timing diagram illustrating generally operation of example ventricular refractory periods (“VRPs”).

Figure 3 is a timing diagram illustrating generally examples of noise windows and of extending a ventricular refractory period.

Figure 4 is a timing diagram illustrating generally examples of a post ventricular refractory period criterion for determining whether a present RR interval since the last ventricular depolarization should be deemed “shockable.”

5

### **Detailed Description**

In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments  
10 are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changes may be made without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense,  
15 and the scope of the present invention is defined by the appended claims and their equivalents. In the drawings, like numerals describe substantially similar components throughout the several views. Like numerals having different letter suffixes represent different instances of substantially similar components. The term “and/or” refers to a nonexclusive “or” (i.e., “A and/or B” includes both “A and B”  
20 as well as “A or B”).

This document discusses, among other things, a cardiac rhythm management system that synchronizes the delivery of an atrial defibrillation shock to a ventricular depolarization. As one example prerequisite to delivering the atrial shock, a ventricular sensing refractory period must not be extended beyond a first value. As  
25 an alternative example prerequisite, a time after expiration of the refractory period and before occurrence of a subsequent ventricular depolarization must exceed a second value. Other examples are also discussed. The present methods and apparatus will be described in applications involving implantable medical devices including, but not limited to, implantable cardiac rhythm management systems such

as pacemakers, cardioverter/defibrillators, pacer/defibrillators, biventricular or other multi-site coordination devices, and drug delivery systems. However, it is understood that the present methods and apparatus may be employed in unimplanted devices, including, but not limited to, external pacemakers, cardioverter/defibrillators, pacer/defibrillators, biventricular or other multi-site coordination devices, monitors, programmers and recorders, whether such devices are used for providing a diagnostic, a therapy, or both a diagnostic and a therapy.

Figure 1 is a schematic/block diagram illustrating generally one embodiment of portions of the present cardiac rhythm management system **100** and an environment in which it is used. In this embodiment, system **100** includes, among other things, a cardiac rhythm management device **105**, which is coupled by one or more leads, such as **110A-C** to heart **115**. Heart **115** includes at least four chambers: right atrium **115A**, right ventricle **115B**, left atrium **115C**, and left ventricle **115D**.

In one embodiment, lead **110A** includes an electrode associated with right atrium **115A**, such as tip electrode **120** and/or ring electrode **125** for sensing atrial heart signals (including indications of atrial fibrillation) and/or providing atrial pacing pulses. The electrode is “associated” with the particular heart chamber by inserting it into that heart chamber, or by inserting it into a portion of the heart’s vasculature that is close to that heart chamber, or by epicardially placing the electrode outside that heart chamber, or by any other technique of configuring and situating an electrode for sensing signals and/or providing therapy with respect to that heart chamber. Lead **110B** includes an electrode, such as **130** or **135**, for sensing ventricular heart signals and/or providing ventricular pacing pulses. In this example, lead **110B** also includes an electrode, such as right ventricular electrode **135** and/or electrode **136** associated with a right atrium or superior vena cava (SVC), for providing a shock. Lead **110C** includes an shock electrode **138** associated with a coronary sinus vessel extending from right atrium **115A** toward left atrium **115C**. Device **105** may also include other electrodes, such as housing electrode **140** and/or header electrode **145**, which are useful for, among other things, unipolar sensing of heart signals and/or unipolar delivery of contraction-evoking

pacing stimulations or defibrillation shocks in conjunction with one or more of the electrodes **120**, **125**, **130**, **135**, **136**, and **138** associated with heart **115**.

Alternatively, bipolar sensing and/or pacing and/or defibrillation may be used, such as bipolar atrial sensing and/or pacing between electrodes **120** and **125**, ventricular sensing and/or pacing between electrodes **130** and **135**.

5           Device **105** includes a sensing module. The sensing module includes an atrial sensing channel **150** and a ventricular sensing channel **155**, each of which is coupled to one or more of the electrodes for sensing electrical depolarizations, corresponding to heart chamber contractions. Such electrical depolarizations of the heart tissue include atrial depolarizations, referred to as P-waves, and ventricular  
10   depolarizations, referred to as QRS complexes. A typical QRS complex is a rapid sequence of three signal excursions away from a baseline in sequentially switching polarity, with the first excursion referred to as a Q-wave, the second (typically the largest) excursion referred to as an R-wave, and the third excursion referred to as the S-wave. A ventricular heart signal also includes ventricular repolarizations, referred  
15   to as T-waves, which occur after respective QRS complexes in preparation for a subsequent ventricular contraction. In one embodiment, atrial sensing channel **150** includes a peak detector for detecting a P-wave peak, and ventricular sensing channel **155** includes a peak detector for detecting an R-wave peak. The atrial depolarizations sensed by atrial sensing channel **150** provide an indication of  
20   detected atrial arrhythmias, such as atrial fibrillation. Device **105** also includes an atrial therapy module **160**, coupled to one or more electrodes for delivering an atrial defibrillation shock to interrupt an episode of atrial fibrillation detected by atrial sensing channel **150**. In one example, the atrial defibrillation shock is delivered between: (1) the housing electrode **140**; and (2) the commonly connected left  
25   ventricular shock electrode **135** and superior vena cava electrode **136**. In another example, the atrial defibrillation shock is delivered between: (1) the housing electrode **140**; and (2) the commonly connected superior vena cava electrode **136** and coronary sinus electrode **138**. In one embodiment, device **105** also includes a ventricular therapy module **162**, coupled to one or more ventricular electrodes, such



as electrodes **130** and/or **135**, for delivering a ventricular pacing pulse to induce a ventricular heart contraction. In a further embodiment, ventricular therapy module **162** is coupled to one or more electrodes, such as electrodes **135**, **136**, and **140** for delivering ventricular defibrillation shocks to interrupt an episode of ventricular fibrillation detected by ventricular sensing channel **155**.

5           Device **105** also includes a controller **165** or other microsequencer capable of executing instructions. Controller **165** is coupled by bus **170** to atrial sensing channel **150**, ventricular sensing channel **155**, atrial therapy module **160** and ventricular therapy module **162**. In one embodiment, controller **165** is also coupled by bus **175** to telemetry transceiver **180**, which is configured for wireless  
10       communication with a remote device, such as external programmer **185**.

          Controller **165** includes an RR interval timer **190**. RR interval timer **190** measures a present RR interval since the last ventricular contraction. The present RR interval is initiated either by the last R-wave detected by ventricular sensing channel **155** (or by the delivery of a ventricular pacing pulse by ventricular therapy  
15       module **162**). The present RR interval measures the time since the last sensed or paced ventricular contraction up to the present point in time. RR interval timer **190** is reset by the next sensed or paced ventricular contraction, which concludes the present RR interval, and which initiates a new present RR interval. In one embodiment, controller **165** also includes one or more memory locations for storing  
20       one or more respective previous values of the RR interval for earlier cardiac cycles.

          Controller **165** also includes a ventricular refractory timer **192**. The ventricular refractory timer times a ventricular sensing refractory period (“ventricular refractory period” or “VRP”) that is initiated by the last R-wave detected by ventricular sensing channel **155** (or by the delivery of a ventricular  
25       pacing pulse by ventricular therapy module **162**). The ventricular refractory period expires after a default time duration (which may be different depending upon whether the ventricular refractory period was initiated by a sensed ventricular depolarization or a paced ventricular depolarization), unless the ventricular refractory period is extended beyond its default duration, such as discussed below.

During the ventricular refractory period, ventricular heart signals detected as ventricular depolarizations by ventricular sensing channel **155** are deemed “noise,” rather than being recognized as a valid ventricular depolarization that would, among other things, reset the RR interval timer. For example, without the VRP, an early portion of a QRS complex could be recognized as a ventricular depolarization, thereby resetting the RR interval timer, and a later portion of the same portion of the QRS complex could potentially be erroneously detected as a subsequent ventricular depolarization event. Ignoring sensed ventricular heart activity during the VRP avoids falsely detecting such heart activity as ventricular depolarizations and resetting the RR interval timer. In one embodiment, detection of such “noise” during the ventricular refractory period may extend the duration of the ventricular refractory period beyond its default duration, such as discussed below.

Controller **165** also includes an atrial shock control module **194** that, among other things, controls the delivery of an atrial shock by atrial therapy module **160** in response to the detection of an episode of atrial fibrillation by atrial sensing channel **150**. The atrial shock is delivered synchronous to a ventricular depolarization concluding the present RR interval if, among other things, the present RR interval is deemed “shockable,” the criteria for which is discussed below.

Figure **2** is a timing diagram illustrating generally operation of one embodiment of ventricular refractory timer **192** that provides a VRP. During the VRP, sensed ventricular heart activity is deemed noise. Such activity during a VRP is not deemed to be valid ventricular depolarization events, but is instead ignored. Sensed ventricular heart activity detected by ventricular sensing channel **155** after expiration of the VRP is deemed a valid ventricular depolarization if the sensed waveform meets a ventricular sensing criterion (e.g., amplitude, frequency, and/or other characteristics associated with a ventricular depolarization). Figure **2** illustrates a (e.g., 135 millisecond) default VRP initiated by a valid sensed ventricular depolarization, denoted  $V_s$ , and a longer (e.g., 250 millisecond) default VRP initiated by a ventricular pace. In this embodiment, the default value of a pace-initiated VRP is longer than the default value of a sense-initiated VRP;

alternatively, the default value of a pace-initiated VRP could be set equal to that of a sense-initiated VRP.

The VRPs illustrated in Figure 2 are subject to being extended beyond their default values. Figure 3 is a timing diagram providing an example of how ventricular heart activity detected by ventricular sensing channel 155 during a VRP is deemed noise that triggers an (e.g., 40 millisecond) noise window following the detection of the event that is deemed noise. As with the VRP, ventricular heart activity is ignored during the noise window. Moreover, the noise window is used in combination with the VRP and, if the noise window occurs late enough in the VRP, extends the VRP until the time at which the noise window expires. In the example of Figure 3, ventricular heart activity is detected 50 milliseconds after the ventricular sense, which triggers a 40 millisecond noise window that expires at 90 milliseconds after the ventricular sense. Figure 3 also illustrates that ventricular heart activity occurring during this noise window, at 70 milliseconds after the ventricular sense, triggers another noise window that expires at 110 milliseconds after the ventricular sense. Figure 3 also illustrates that ventricular heart activity occurring at 130 milliseconds triggers a noise window that extends the ventricular refractory period beyond its default value of 135 milliseconds until the noise window expires at 170 milliseconds after the ventricular sense. Other detection of ventricular heart activity during the noise-window extended VRP would similarly trigger a (e.g., 40 millisecond) noise window further extending the VRP.

As discussed above, device 105 delivers an atrial shock synchronous to the next (paced or sensed) ventricular contraction to interrupt an episode of atrial fibrillation, provided that the present RR interval (i.e., the time since the last sensed or paced ventricular contraction) is deemed “shockable.” In one embodiment, a shockable RR interval requires, among other things, that a VRP associated with the present RR interval must be less than or equal to a first predetermined value. In this example, a sensed ventricular contraction triggers a different default VRP than a paced ventricular contraction. A sensed ventricular contraction typically triggers a default VRP that is set at approximately between 95 milliseconds and 250

milliseconds, such as about 135 milliseconds. A paced ventricular contraction typically triggers a default VRP that is set at approximately between 150 milliseconds and 500 milliseconds, such as about 250 milliseconds. As discussed above, noise sensed during the VRP may extend the VRP from its default value. In one embodiment, the first predetermined value to which the VRP is compared for a sense-triggered VRP is different from the first predetermined value to which the VRP is compared for a pace-triggered VRP, such as where the default VRP values are different depending on whether sense-triggered or pace-triggered, as in the example of Figure 2. In one embodiment, the first predetermined value is set equal to the default sense-triggered VRP when the present RR interval is initiated by a sensed ventricular depolarization, and set equal to the default pace-triggered VRP when the present RR interval is initiated by a paced ventricular depolarization. In such an example, any noise-window extension of the VRP will result in the present RR interval being deemed “not shockable.”

For a sensed-triggered VRP, the first predetermined value is set at the same value as the default sense-triggered VRP (e.g., at about 135 milliseconds in the example of Figure 3); if the VRP exceeds this value (such as by noise-window extension), the present RR interval is deemed “not shockable,” and delivery of the atrial shock is delayed until a subsequent cardiac cycle. For example, in the scenario illustrated in Figure 3, in which the VRP is extended beyond 135 milliseconds to 170 milliseconds due to the illustrated noise window, the present RR interval initiated by the illustrated ventricular sense would be deemed not shockable because of its extension beyond the 135 millisecond default sensed VRP.

For a pace-triggered VRP, the first predetermined value is set at the same value as the default pace-triggered VRP (e.g., at about 250 milliseconds in the example of Figure 2); if the VRP exceeds this value (such as by noise-window extension), the present RR interval is deemed “not shockable,” and delivery of the atrial shock is delayed until a subsequent cardiac cycle.

In one embodiment, the shockable present RR interval requirement of a ventricular refractory period is less than or equal to a first predetermined value is

used in conjunction with at least one other condition for deeming the present RR interval to be shockable. Marchovecchio et al. U.S. patent application serial number 09/661,875 entitled "Method for Delivering Atrial Defibrillation Therapy," and assigned to Cardiac Pacemakers, Inc., which is incorporated herein by reference in its entirety, sets forth additional conditions for deeming a present RR interval to be

5 shockable. One such condition, used in conjunction with the instant requirement that the ventricular refractory period is less than or equal to a first predetermined value, is that the present RR interval duration must be longer than a preceding QT interval (i.e., between the Q-wave of the ventricular depolarization and a subsequent T-wave associated with a ventricular repolarization) duration by a second

10 predetermined value (e.g., a second predetermined value providing a therapy margin that is approximately between 0 milliseconds and 200 milliseconds, such as about 60 milliseconds). The preceding QT interval need not be measured, it can instead be estimated from the measured value of the preceding RR interval (i.e., the RR interval concluded by the most recently detected (or paced) ventricular contraction

15 and initiated by an immediately preceding paced or sensed ventricular contraction. A second, alternative, condition used in conjunction with the instant requirement that the ventricular refractory period is less than or equal to a first predetermined value, is that the present RR interval duration is longer than the preceding QT interval by the second predetermined value (or some other therapy margin), and the

20 present RR interval duration is longer than a third predetermined value (e.g., a third predetermined value providing a minimum interval duration that is approximately between 350 milliseconds and 1000 milliseconds, such as about 500 milliseconds). A third, alternative, condition used in conjunction with the instant requirement that the ventricular refractory period is less than or equal to a first predetermined value,

25 is that the present RR interval duration is longer than a fourth predetermined value, in which the fourth predetermined value is greater than the third predetermined value. In one embodiment, the fourth predetermined value is a minimum interval duration that is approximately between 500 milliseconds and 1000 milliseconds, such as about 700 milliseconds, or such as about 800 milliseconds.

Chen et al. U.S. patent application serial number 09/316,741 entitled  
“Cardiac Rhythm Management System With Atrial Shock Timing Optimization,”  
and assigned to Cardiac Pacemakers, Inc., which is incorporated herein by reference  
in its entirety, sets forth additional conditions for deeming a present RR interval to  
be shockable. One such condition, used in conjunction with the instant requirement  
5 that the ventricular refractory period is less than or equal to a first predetermined  
value, is that the present RR interval duration is longer than the preceding RR  
interval by a fifth predetermined value (e.g., a fifth predetermined value that is  
approximately between 0 milliseconds and 200 milliseconds, such as about 90  
milliseconds), and the present RR interval duration is longer than a sixth  
10 predetermined value (e.g., the sixth predetermined value providing a minimum  
interval that is approximately between 350 milliseconds and 1000 milliseconds,  
such as about 500 milliseconds). A second such condition, used in conjunction with  
the instant requirement that the ventricular refractory period is less than or equal to a  
first predetermined value, is that the present RR interval duration is longer than a  
15 seventh predetermined value (e.g., a seventh predetermined value that is  
approximately between 500 milliseconds and 1000 milliseconds, such as about 700  
milliseconds or 800 milliseconds, in which the seventh predetermined value is  
greater than the sixth predetermined value.

Another possible condition, used in conjunction with the instant requirement  
20 that the ventricular refractory period is less than or equal to a first predetermined  
value, is that the present RR interval’s initiating and concluding ventricular  
depolarizations not be paced and sensed, respectively. In such a situation, where the  
present RR interval is initiated by a paced ventricular depolarization, and the present  
RR interval is concluded by a sensed ventricular depolarization, the present RR  
25 interval is deemed “not shockable,” and delivery of the atrial shock is delayed until  
a subsequent cardiac cycle.

In an alternative embodiment, the instant requirement that the ventricular  
refractory period is less than or equal to a first predetermined value, is replaced by  
an alternative requirement that a post-refractory ventricular sensing period (i.e.,

between expiration of the ventricular refractory period and the subsequent sensed or paced ventricular contraction) exceeds an eighth predetermined value (e.g., an eighth predetermined value that is approximately between 265 milliseconds and 565 milliseconds such as about 365 milliseconds). This ensures a sufficiently long post-VRP ventricular sensing period for detecting a ventricular heart contraction (or  
5 alternatively, delivering a ventricular pacing pulse if the present RR interval exceeds an “escape interval” timeout corresponding to the indicated heart rate being maintained by the device 105). This is illustrated in Figure 4 by requiring that the post-VRP ventricular sensing time period,  $T_{\text{POST-VRP}}$ , equals or exceeds a minimum required value,  $\text{MIN}_{\text{POST-VRP}}$  that is approximately between 265 milliseconds and 565  
10 milliseconds, such as about 365 milliseconds. In one embodiment, if minimum ventricular sensing time period requirement is met, then the present RR interval is deemed shockable and an atrial shock is delivered synchronous to (although permissibly delayed a bit from) the ventricular event concluding the present RR interval, as illustrated in Figure 4. Other requirements may be imposed in  
15 conjunction with this requirement for delivering the atrial shock, such as discussed above with respect to the maximum VRP requirement.

### Conclusion

This document describes a cardiac rhythm management system that, among  
20 other things, synchronizes the delivery of an atrial defibrillation shock to a ventricular depolarization if the present RR interval is deemed shockable. Possible prerequisites for deeming the present RR interval shockable include, among other things, determining whether a ventricular refractory period exceeds a particular value, or determining whether a post-ventricular sensing period exceeds a particular  
25 value.

It is to be understood that the above description is intended to be illustrative, and not restrictive. For example, the above-described embodiments may be used in combination with each other. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention

should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.”